Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo
Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in the MoneyShow Las Vegas Virtual Expo from August 18 to 20, 2020. The company's presentation is scheduled for August 19 at 4:50 PM ET, led by Chairman Leonard Mazur. Key topics include the recent $9.6 million public stock offering and a briefing to the FDA regarding Mino-Wrap, aimed at reducing post-operative infections. Investors can register for the event to access the live webcast.
- None.
- None.
Insights
Analyzing...
CRANFORD, N.J., Aug. 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Las Vegas Virtual Expo that is being held August 18 – 20, 2020.
Event: MoneyShow Las Vegas Virtual Expo
Presentation Date: Wednesday, August 19, 2020
Presentation Time: 4:50 PM ET
Mr. Leonard Mazur, Chairman of Citius, will provide an overview of the Company, including the recent closing of a
To listen to the live webcast, investors will need to register for the MoneyShow Las Vegas Virtual Expo first at the following link:
Once registered, investors can then access the MoneyShow Las Vegas Virtual Expo platform beginning the morning of August 18, 2020 at:
https://online.moneyshow.com/2020/august/moneyshow-las-vegas-virtual-expo/platform/login
About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.
Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-moneyshow-las-vegas-virtual-expo-301111898.html
SOURCE Citius Pharmaceuticals, Inc.